Enter your email address below to login:
About the Webinar
Single-cell analysis technologies have matured rapidly in the last decade and are being applied to many aspects of cancer biology. The next challenge for these technologies will be to find applications with real-world impact. In this episode we consider the likely uses of single-cell analysis in cancer, and discuss how these technologies might be integrated into clinical practice.
Continue the conversation on @ozsinglecells #OzSingleCell
For technical assistance, please phone Redback Connect on 1800 733 416.
Click here to test your system before the webinar.
Associate Professor Nicholas Navin - MD Anderson Cancer Center
Dr. Navin is an Associate Professor at MD Anderson Cancer Center, with a joint appointment in the Department of Bioinformatics. Dr. Navin’s group continues to pioneer the developing novel technologies for performing single cell DNA and RNA sequencing, in addition to innovative computational and statistical methods for analyzing the resulting large-scale datasets. These methods are being applied to study cancer evolution in the context of invasion, metastasis and therapy resistance. His laboratory works closely with leading oncologists and pathologist at MD Anderson to translate these technologies into the clinic, where they are poised to make a major impact on reducing the morbidity in human patients.
Dr Venessa Chin - Garvan Institute of Medical Research
Venessa is a Medical Oncologist working at The Kinghorn Cancer Centre in the fields of lung and head and neck cancer. She is also a post-doctoral research officer in the Garvan-Weizmann Centre for Cellular Genomics where she is studying the clinical applications of cellular genomics in lung and head and neck cancer.
Dr Charis Teh – Walter and Eliza Hall Institute
Dr Charis Teh is a Research Fellow at the Walter and Eliza Hall Institute of Medical Research. Her research attempts to identify the ‘kill switch’ that triggers cell suicide in cancers. Using cutting-edge technologies, she profiles an extensive network of life and death proteins in cancer cells to discover the most potent druggable killers.
Dr Heather Lee
Heather is a biomedical scientist with experience in developmental biology, cancer biology and epigenetics. She is fascinated by the enormous diversity of cell types present in the human body, and by the importance of this cellular heterogeneity in cancer management. During her post-doctoral studies, Heather developed the first method for analysis of genome-wide DNA methylation in single cells. Since joining the University of Newcastle in 2017, Heather has been applying this technique to understand epigenetic heterogeneity in acute myeloid leukaemia.
Dr Helen McGuire
ASI NSW Councillor | President Elect ACS | ISAC Marylou Ingram Scholar
Dr Helen McGuire is a Senior Research Fellow at the Ramaciotti Facility for Human Systems Biology, an initiative established in 2013 to support the development of mass cytometry within NSW. Her research focus and interests lie in the clinical application of immunological studies to a range of human diseases including coordinating a large cancer program, and she is particularly passionate about applying recent technological advances such as mass cytometry to facilitate comprehensive immune-profiling.
This episode is brought to you by BD and BGI Genomics